EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Zhijuan Liu iD, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng und 9 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70161 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Zhijuan Liu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology/Oncology, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Development Program of Jinan Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management.

Methods

A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐NHL‐2017‐lymphoblastic lymphoma regimen from April 2017 to March 2023.

Results

Among the 256 patients, the median age at diagnosis was 5.0 years, with a slight male predominance. Subcutaneous tissues, skin, and osteolytic bone were the most common sites of the disease. More than 90% of patients exhibited disseminated disease (Stage III or IV). Approximately 19.9% of the diagnosed patients exhibited central nervous system involvement. Adverse events were observed in 33 patients (12.9%), with disease progression or relapse occurring in 10.2% of cases, particularly linked to unfavorable outcomes in instances of early relapse or progression. Salvage chemotherapy combined with immunotherapies, followed by bridging hematopoietic stem cell transplantation, significantly improved the prognosis of relapse and disease progression in children. Overall, the follow‐up time was 37.6 (Q1–Q3, 28.9–38.0) months, and 3‐year event‐free survival rate and overall survivals were 86.3% ± 2.5% and 95.2% ± 1.5%, respectively, with a treatment‐related mortality of 1.6%. Multivariate analysis showed that poor prednisone response and no complete remission on Day 33 of induction were risk factors for poor prognosis.

Conclusion

The CNCL‐NHL‐2017‐lymphoblastic lymphoma regimen was effective in children with B‐LBL. The response to initial treatment is vital for improving prognosis in patients with B‐LBL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationHumansMaleChildRetrospective StudiesChild, PreschoolFemalePrognosisAdolescentRisk FactorsChinaSurvival RateInfantFollow-Up Studies

Stichwörter der Autor:innen

childprecursor B‐cell lymphoblastic lymphomaprognosisrisk factors

Autor:innen und Institutionen

  • Department of Pediatric Hematology/Oncology, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan, China.
  • Department of Hematology and Oncology, Anhui Provincial Children's Hospital, Hefei, China.
  • Medical Oncology Department, Pediatric Oncology Center, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
  • Department of Pediatrics, Peking University People's Hospital, Beijing, China.
  • Department of Pediatric Hematology/Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Hematology and Oncology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Zhijuan Liu, Xiaowen Zhai

Förderung

  • Science and Technology Development Program of Jinan Municipal Health Commission

Zitieren

APA

Liu, Z., Wang, J., Jin, L., Duan, Y., Li, F., Jia, Y., Zhang, L., Yuan, X., Liu, W., Liu, Y., Liu, A., Zheng, M., Dai, Y., Jiang, L., Sun, L., Zhai, X., Liu, R., Zhou, C., Gao, Z., …, & Yang, X. (2026). Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70161

Vancouver

Liu Z, Wang J, Jin L, Duan Y, Li F, Jia Y, et al. Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70161

BibTeX
@article{Liu2026,
  author = {Liu, Zhijuan and Wang, Jian and Jin, Ling and Duan, Yanlong and Li, Fu and Jia, Yueping and Zhang, Leping and Yuan, Xiaojun and Liu, Wei and Liu, Ying and Liu, Ansheng and Zheng, Mincui and Dai, Yunpeng and Jiang, Lian and Sun, Lirong and Zhai, Xiaowen and Liu, Rong and Zhou, Chunju and Gao, Zifen and Zhang, Yonghong and Yang, Xiaomei},
  title = {Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70161}
}
Kostenlos starten →